The Role of the Cardiac Biomarkers in the Renal Cell Carcinoma Multidisciplinary Management
Renal cell carcinoma, an aggressive malignancy, is often incidentally diagnosed. The patient remains asymptomatic to the late stage of the disease, when the local or distant metastases are already present. Surgical treatment remains the choice for these patients, although the plan must adapt to the...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/13/11/1912 |
| _version_ | 1797597716823408640 |
|---|---|
| author | Anca Drăgan Ioanel Sinescu |
| author_facet | Anca Drăgan Ioanel Sinescu |
| author_sort | Anca Drăgan |
| collection | DOAJ |
| description | Renal cell carcinoma, an aggressive malignancy, is often incidentally diagnosed. The patient remains asymptomatic to the late stage of the disease, when the local or distant metastases are already present. Surgical treatment remains the choice for these patients, although the plan must adapt to the characteristics of the patients and the extension of the neoplasm. Systemic therapy is sometimes needed. It includes immunotherapy, target therapy, or both, with a high level of toxicity. Cardiac biomarkers have prognosis and monitoring values in this setting. Their role in postoperative identification of myocardial injury and heart failure already have been demonstrated, as well as their importance in preoperative evaluation from the cardiac point of view and the progression of renal cancer. The cardiac biomarkers are also part of the new cardio-oncologic approach to establishing and monitoring systemic therapy. They are complementary tests for assessment of the baseline toxicity risk and tools to guide therapy. The goal must be to continue the treatment as long as possible with the initiation and optimisation of the cardiological treatment. Cardiac atrial biomarkers are reported to have also antitumoral and anti-inflammatory properties. This review aims to present the role of cardiac biomarkers in the multidisciplinary management of renal cell carcinoma patients. |
| first_indexed | 2024-03-11T03:09:25Z |
| format | Article |
| id | doaj.art-48155ca1ae8e4ce78cc8636855e6d7a4 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-11T03:09:25Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-48155ca1ae8e4ce78cc8636855e6d7a42023-11-18T07:42:47ZengMDPI AGDiagnostics2075-44182023-05-011311191210.3390/diagnostics13111912The Role of the Cardiac Biomarkers in the Renal Cell Carcinoma Multidisciplinary ManagementAnca Drăgan0Ioanel Sinescu1Department of Cardiovascular Anaesthesiology and Intensive Care, Prof. C.C. Iliescu Emergency Institute for Cardiovascular Diseases, 258 Fundeni Road, 022328 Bucharest, RomaniaDepartment of Urological Surgery, Dialysis and Kidney Transplantation, Fundeni Clinical Institute, 258 Fundeni Road, 022328 Bucharest, RomaniaRenal cell carcinoma, an aggressive malignancy, is often incidentally diagnosed. The patient remains asymptomatic to the late stage of the disease, when the local or distant metastases are already present. Surgical treatment remains the choice for these patients, although the plan must adapt to the characteristics of the patients and the extension of the neoplasm. Systemic therapy is sometimes needed. It includes immunotherapy, target therapy, or both, with a high level of toxicity. Cardiac biomarkers have prognosis and monitoring values in this setting. Their role in postoperative identification of myocardial injury and heart failure already have been demonstrated, as well as their importance in preoperative evaluation from the cardiac point of view and the progression of renal cancer. The cardiac biomarkers are also part of the new cardio-oncologic approach to establishing and monitoring systemic therapy. They are complementary tests for assessment of the baseline toxicity risk and tools to guide therapy. The goal must be to continue the treatment as long as possible with the initiation and optimisation of the cardiological treatment. Cardiac atrial biomarkers are reported to have also antitumoral and anti-inflammatory properties. This review aims to present the role of cardiac biomarkers in the multidisciplinary management of renal cell carcinoma patients.https://www.mdpi.com/2075-4418/13/11/1912renal cell carcinomacardio-oncologyrisk assessmentglobal longitudinal straincardiac biomarkers |
| spellingShingle | Anca Drăgan Ioanel Sinescu The Role of the Cardiac Biomarkers in the Renal Cell Carcinoma Multidisciplinary Management Diagnostics renal cell carcinoma cardio-oncology risk assessment global longitudinal strain cardiac biomarkers |
| title | The Role of the Cardiac Biomarkers in the Renal Cell Carcinoma Multidisciplinary Management |
| title_full | The Role of the Cardiac Biomarkers in the Renal Cell Carcinoma Multidisciplinary Management |
| title_fullStr | The Role of the Cardiac Biomarkers in the Renal Cell Carcinoma Multidisciplinary Management |
| title_full_unstemmed | The Role of the Cardiac Biomarkers in the Renal Cell Carcinoma Multidisciplinary Management |
| title_short | The Role of the Cardiac Biomarkers in the Renal Cell Carcinoma Multidisciplinary Management |
| title_sort | role of the cardiac biomarkers in the renal cell carcinoma multidisciplinary management |
| topic | renal cell carcinoma cardio-oncology risk assessment global longitudinal strain cardiac biomarkers |
| url | https://www.mdpi.com/2075-4418/13/11/1912 |
| work_keys_str_mv | AT ancadragan theroleofthecardiacbiomarkersintherenalcellcarcinomamultidisciplinarymanagement AT ioanelsinescu theroleofthecardiacbiomarkersintherenalcellcarcinomamultidisciplinarymanagement AT ancadragan roleofthecardiacbiomarkersintherenalcellcarcinomamultidisciplinarymanagement AT ioanelsinescu roleofthecardiacbiomarkersintherenalcellcarcinomamultidisciplinarymanagement |